CN1739588A - Chinese medicine prepn for treating cardiac vascular diseases and its prepn - Google Patents
Chinese medicine prepn for treating cardiac vascular diseases and its prepn Download PDFInfo
- Publication number
- CN1739588A CN1739588A CN 200510032114 CN200510032114A CN1739588A CN 1739588 A CN1739588 A CN 1739588A CN 200510032114 CN200510032114 CN 200510032114 CN 200510032114 A CN200510032114 A CN 200510032114A CN 1739588 A CN1739588 A CN 1739588A
- Authority
- CN
- China
- Prior art keywords
- preparation
- adjuvant
- micropill
- gained
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 230000000747 cardiac effect Effects 0.000 title abstract 2
- 208000019553 vascular disease Diseases 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 claims abstract description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 18
- 239000006190 sub-lingual tablet Substances 0.000 claims abstract description 18
- 229940098466 sublingual tablet Drugs 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 5
- 238000010992 reflux Methods 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000011347 resin Substances 0.000 claims abstract description 4
- 229920005989 resin Polymers 0.000 claims abstract description 4
- 239000002671 adjuvant Substances 0.000 claims description 20
- 239000007919 dispersible tablet Substances 0.000 claims description 16
- 208000019622 heart disease Diseases 0.000 claims description 16
- -1 polypropylene Polymers 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000001856 Ethyl cellulose Substances 0.000 claims description 10
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 10
- 229920001249 ethyl cellulose Polymers 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
- 239000000470 constituent Substances 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000004925 Acrylic resin Substances 0.000 claims description 4
- 229920000178 Acrylic resin Polymers 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 229920000126 latex Polymers 0.000 claims description 4
- 239000004816 latex Substances 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 230000000274 adsorptive effect Effects 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 2
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004380 Cholic acid Substances 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 229920006218 cellulose propionate Polymers 0.000 claims description 2
- 235000019416 cholic acid Nutrition 0.000 claims description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 2
- 229960002471 cholic acid Drugs 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 2
- FHQMKMYTNSVUAT-UHFFFAOYSA-N dioctyl benzene-1,2-dicarboxylate ethenyl acetate Chemical compound C(C=1C(C(=O)OCCCCCCCC)=CC=CC1)(=O)OCCCCCCCC.C(C)(=O)OC=C FHQMKMYTNSVUAT-UHFFFAOYSA-N 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- LUJQXGBDWAGQHS-UHFFFAOYSA-N ethenyl acetate;phthalic acid Chemical compound CC(=O)OC=C.OC(=O)C1=CC=CC=C1C(O)=O LUJQXGBDWAGQHS-UHFFFAOYSA-N 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920006389 polyphenyl polymer Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 229960002622 triacetin Drugs 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 abstract description 4
- 230000006837 decompression Effects 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract description 3
- 229940023488 pill Drugs 0.000 abstract description 3
- 239000006187 pill Substances 0.000 abstract description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 3
- 229940116229 borneol Drugs 0.000 abstract 3
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 3
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 3
- 239000002270 dispersing agent Substances 0.000 abstract 2
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000009982 suxiao jiuxinwan Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The Chinese medicine preparation for treating cardiac vascular diseases is prepared with Chuanxiong rhizome and borneol as main material and may be prepared into quick acting micro pill, dispersant tablet or sublingual tablet. The preparation process includes separately crushing Chuanxiong rhizome and borneol into fine powder, reflux extraction of fine Chuanxiong rhizome powder with alcohol, decompression concentrating the extracted liquid, macroporous resin column adsorption, water washing, eluting with alcohol, decompression concentrating the eluted liquid, adding fine borneol powder, mixing homogeneously, adding proper amount of supplementary material, and further preparation into micro pill, dispersant tablet or sublingual tablet. The preparation has high medicinal effect.
Description
Technical field:
The present invention relates to a kind of Chinese medicine preparation and preparation method thereof, relate in particular to a kind of Chinese medicine preparation for the treatment of cardiovascular disease and preparation method thereof.
Background technology:
The existing dosage form of fast-acting heart disease curing has only drop pill by retrieval, has listed 18 in Chinese traditional patent formulation preparation promulgated by the ministries or commissions of the Central Government in.By patent retrieval, the Tianjin No.6 Chinese Medicines Factory is in 98 patents of having applied for the SUXIAO JIUXIN WAN manufacturing process, Zhang Qinglong has applied for the patent of a kind of fast-acting heart disease curing oral cavity disintegration tablet and preparation method thereof in calendar year 2001, University Of Tianjin has applied for the patent of fast-acting heart disease curing oral cavity disintegration tablet and preparation method, the relevant patent of no fast-acting heart disease curing micropill or dispersible tablet or Sublingual tablet in 2004.
Micropill in the Chinese medicine preparation or dispersible tablet or Sublingual tablet, change dosage form or technology and manage as new drug research according to the relevant laws and regulations of China's drug control as a kind of pharmaceutical dosage form.Micropill has at the gastrointestinal tract distribution area big, the bioavailability height, and zest is little, because particle diameter is little, is subjected to digestive tract to carry the food rhythm and pace of moving things to influence little (close as pylorus etc.), good fluidity, size evenly is easy to handle (as coating, divided dose); Dispersible tablet has good dispersing state, and disintegration time is short, and the medicine stripping is rapid, absorbs soon, and the bioavailability height, can be swallowed, chew to contain and suck or with taking after the aqueous dispersion taking convenience; Advantages such as Sublingual tablet can prevent that the different pH value of gastrointestinal tract to the influence of medicine and the digestive enzyme destruction to medicine, also can avoid the liver first-pass effect of medicine, and is rapid-action.
Existing SUXIAO JIUXIN WAN technology features is to get Rhizoma Chuanxiong in the prescription, extract with alcohol heating reflux, the extracting solution decompression recycling ethanol adds hydrochloric acid and regulates pH value, use chloroform extraction, chloroform layer adds hydrochloric acid, leaves standstill, and separates, water layer is regulated pH with ammonia, the reuse chloroform extraction, the reclaim under reduced pressure chloroform, solution concentration gets Rhizoma Chuanxiong extract; With the Polyethylene Glycol heating and melting, add Rhizoma Chuanxiong extract and Borneolum Syntheticum immediately, stir, splash in the liquid paraffin, promptly.
Existing SUXIAO JIUXIN WAN needs special equipment, cost height, complicated process of preparation etc.
Summary of the invention:
The purpose of this invention is to provide a kind of Chinese medicine preparation for the treatment of cardiovascular disease and preparation method thereof, overcome the above-mentioned drawback of prior art, improved the quality of product, satisfied the needs of medical treatment better.
The objective of the invention is to be achieved through the following technical solutions.
A kind of Chinese medicine preparation for the treatment of cardiovascular disease, it is that main constituent is fast-acting heart disease curing micropill or the dispersible tablet or the Sublingual tablet of Rhizoma Chuanxiong, Borneolum Syntheticum.
Its preparation method is:
(1) medicine constituent and percentage by weight thereof are as follows:
Rhizoma Chuanxiong 65.3-88.4%, Borneolum Syntheticum 11.6-34.7%;
Medicine constituent optimum weight percentage ratio is:
Rhizoma Chuanxiong 76.9%, Borneolum Syntheticum 23.1%;
(2) get Rhizoma Chuanxiong, the Borneolum Syntheticum pulverize separately becomes fine powder, and is standby;
(3) get (2) gained Rhizoma Chuanxiong fine powder, use alcohol reflux 2-3 time, merge extractive liquid,, concentrating under reduced pressure, the macroporous adsorptive resins of flowing through again washes with water earlier, and reuse 20-50% ethanol carries out eluting, collects eluent, and concentrating under reduced pressure gets Rhizoma Chuanxiong extract, and is standby;
(4) get (3) gained Rhizoma Chuanxiong extract, add (2) gained Borneolum Syntheticum fine powder, mixing, it is standby to get hybrid medicine;
(5) get (4) gained hybrid medicine, add suitable adjuvant, mixing is made micropill or dispersible tablet or Sublingual tablet;
The preparation method of its micropill: get (4) gained hybrid medicine, add an amount of adjuvant, mix homogeneously is granulated, and coating or coating are not made the micropill of diameter less than 2.5mm, promptly get the fast-acting heart disease curing micropill;
The micropill adjuvant is following one or more combinations or other suitable adjuvant, uses with by arbitrary proportion: ethyl cellulose (EC), the polypropylene polysiloxanes, the wax class, Polyethylene Glycol (PEG), stearic acid, Lac, acrylic resin, polyvinyl alcohol, polyvinylpyrrolidone (PVP), methylcellulose, hydroxypropyl cellulose, cellulose propionate, the acrylic resin aqueous dispersion, the pseudo-latex of ethyl cellulose, cellulose acetate-phthalate (CAP) latex, polyphenyl dioctyl phthalate vinyl acetate (PVAP) aqueous dispersion, propylene glycol, glycerol, triacetin, acetyl list monoglyceride, phthalic acid ester, polyoxyethylene sorbitan monoleate, sodium lauryl sulphate, lactose, fructose, sucrose;
The preparation method of its dispersible tablet: get the hybrid medicine of (4) gained, add an amount of adjuvant, mix homogeneously, granulation, dry, granulate, tabletting promptly gets the fast-acting heart disease curing dispersible tablet;
Adjuvant is that one or more mixture or other suitable adjuvant used with by arbitrary proportion in the following material: low-substituted hydroxypropyl cellulose, dimension splash form sediment 5000, polyvinylpolypyrrolidone 1NF-10, Polyethylene Glycol, polyvidon class, methylcellulose, ethyl cellulose, hydroxypropyl emthylcellulose, cellulose acetate-phthalate, hydroxypropyl methylcellulose phthalate, hydroxymethyl ethyl cellulose, microcrystalline Cellulose, citric acid, cholic acid, fumaric acid, succinic acid, tartaric acid, colloidality silicon dioxide, magnesium stearate, Pulvis Talci;
The preparation method of its Sublingual tablet: get the hybrid medicine of (4) gained, add an amount of adjuvant, mix homogeneously, drying is pressed into Sublingual tablet;
Adjuvant is that one or more mixture or other suitable adjuvants used with by arbitrary proportion in the following material: carboxymethyl starch sodium, xylitol, sorbitol, lactose, sucrose, silicon dioxide, micropowder silica gel, tween 80, polyvinylpyrrolidone, mannitol, magnesium stearate.
Specific embodiments:
The present invention further specifies in conjunction with specific embodiments, can be for reference, but do not limit the scope of the invention:
A kind of Chinese medicine preparation for the treatment of cardiovascular disease, it is that main constituent is fast-acting heart disease curing micropill or the dispersible tablet or the Sublingual tablet of Rhizoma Chuanxiong, Borneolum Syntheticum.
A kind of Chinese medicine preparation for the treatment of cardiovascular disease of the present invention has promoting flow of QI and blood, stasis-dispelling and pain-killing, coronary blood flow increasing, allevating angina pectoris.Be mainly used in qi stagnation and blood stasis type coronary heart disease, angina pectoris.
Of the present inventionly a kind ofly treat the Chinese medicine preparation fast-acting heart disease curing micropill of cardiovascular disease or the preparation method of dispersible tablet or Sublingual tablet is:
(1) medicine constituent and weight consumption thereof are as follows:
Rhizoma Chuanxiong 100g, Borneolum Syntheticum 30g;
(2) get Rhizoma Chuanxiong, the Borneolum Syntheticum pulverize separately becomes fine powder, and is standby;
(3) get (2) gained Rhizoma Chuanxiong fine powder, use alcohol reflux 2 times, merge extractive liquid,, concentrating under reduced pressure, the macroporous adsorptive resins of flowing through again washes with water earlier, and reuse 30% ethanol carries out eluting, collects eluent, and concentrating under reduced pressure gets Rhizoma Chuanxiong extract, and is standby;
(4) get (3) gained Rhizoma Chuanxiong extract, add (2) gained Borneolum Syntheticum fine powder, mixing, it is standby to get hybrid medicine;
(5) a kind of Chinese medicine preparation fast-acting heart disease curing micropill for the treatment of cardiovascular disease, its preparation method is to get (4) gained hybrid medicine, with 30g dextrin mix homogeneously, 5%PVP alcohol liquid is binding agent, at first prepare 60 purpose granules and make parent nucleus, be binding agent with 5%PVP alcohol liquid again, add the mixed powder amplification and make 40 purpose micropills, promptly.
(6) a kind of Chinese medicine preparation fast-acting heart disease curing dispersible tablet for the treatment of cardiovascular disease, its preparation method is to get (4) gained hybrid medicine, adds cross-linking polyethylene pyrrolidone 30g, low-substituted hydroxypropyl cellulose 20g, microcrystalline Cellulose 100g, mix homogeneously, the secondary that sieves, the micropowder silica gel of adding 0.5%, mix homogeneously, cross 80 mesh sieve secondaries, tabletting promptly gets dispersible tablet.
(7) a kind of Chinese medicine preparation fast-acting heart disease curing Sublingual tablet for the treatment of cardiovascular disease, its preparation method is a fine drug powder of getting (4) gained, adds lactose 1.5g, sucrose 5g, carboxymethyl starch sodium 1g, magnesium stearate 0.2g, abundant mixing sieves, granulation, granulate, is pressed into Sublingual tablet.
Advantage of the present invention is:
Preparation technology is simple, takes, easy to carry, and constant product quality is conducive to improve drug effect.
Claims (3)
1, a kind of Chinese medicine preparation for the treatment of cardiovascular disease is characterized in that it is that main constituent is fast-acting heart disease curing micropill or the dispersible tablet or the Sublingual tablet of Rhizoma Chuanxiong, Borneolum Syntheticum.
2, a kind of preparation method for the treatment of the Chinese medicine preparation of cardiovascular disease, it is the preparation method of fast-acting heart disease curing micropill or dispersible tablet or Sublingual tablet, it is characterized in that:
(1) medicine constituent and percentage by weight thereof are as follows:
Rhizoma Chuanxiong 65.3-88.4%, Borneolum Syntheticum 11.6-34.7%;
(2) get Rhizoma Chuanxiong, the Borneolum Syntheticum pulverize separately becomes fine powder, and is standby;
(3) get (2) gained Rhizoma Chuanxiong fine powder, use alcohol reflux 2-3 time, merge extractive liquid,, concentrating under reduced pressure, the macroporous adsorptive resins of flowing through again washes with water earlier, and reuse 20-50% ethanol carries out eluting, collects eluent, and concentrating under reduced pressure gets Rhizoma Chuanxiong extract, and is standby;
(4) get (3) gained Rhizoma Chuanxiong extract, add (2) gained Borneolum Syntheticum fine powder, mixing, it is standby to get hybrid medicine;
(5) get (4) gained hybrid medicine, add suitable adjuvant, mixing is made micropill or dispersible tablet or Sublingual tablet;
The preparation method of its micropill: get (4) gained hybrid medicine, add an amount of adjuvant, mix homogeneously is granulated, and coating or coating are not made the micropill of diameter less than 2.5mm, promptly get the fast-acting heart disease curing micropill;
Micropill or pellet capsule adjuvant are following one or more combinations or other suitable adjuvant, use with by arbitrary proportion: ethyl cellulose (EC), the polypropylene polysiloxanes, the wax class, Polyethylene Glycol (PEG), stearic acid, Lac, acrylic resin, polyvinyl alcohol, polyvinylpyrrolidone (PVP), methylcellulose, hydroxypropyl cellulose, cellulose propionate, the acrylic resin aqueous dispersion, the pseudo-latex of ethyl cellulose, cellulose acetate-phthalate (CAP) latex, polyphenyl dioctyl phthalate vinyl acetate (PVAP) aqueous dispersion, propylene glycol, glycerol, triacetin, acetyl list monoglyceride, phthalic acid ester, polyoxyethylene sorbitan monoleate, sodium lauryl sulphate, lactose, fructose, sucrose;
The preparation method of its dispersible tablet: get the hybrid medicine of (4) gained, add an amount of adjuvant, mix homogeneously, granulation, dry, granulate, tabletting promptly gets the fast-acting heart disease curing dispersible tablet;
Adjuvant is that one or more mixture or other suitable adjuvant used with by arbitrary proportion in the following material: low-substituted hydroxypropyl cellulose, dimension splash form sediment 5000, polyvinylpolypyrrolidone 1NF-10, Polyethylene Glycol, polyvidon class, methylcellulose, ethyl cellulose, hydroxypropyl emthylcellulose, cellulose acetate-phthalate, hydroxypropyl methylcellulose phthalate, hydroxymethyl ethyl cellulose, microcrystalline Cellulose, citric acid, cholic acid, fumaric acid, succinic acid, tartaric acid, colloidality silicon dioxide, magnesium stearate, Pulvis Talci;
The preparation method of its Sublingual tablet: get the hybrid medicine of (4) gained, add an amount of adjuvant, mix homogeneously, drying is pressed into Sublingual tablet;
Adjuvant is that one or more mixture or other suitable adjuvants used with by arbitrary proportion in the following material: carboxymethyl starch sodium, xylitol, sorbitol, lactose, sucrose, silicon dioxide, micropowder silica gel, tween 80, polyvinylpyrrolidone, mannitol, magnesium stearate.
3, a kind of preparation method for the treatment of the Chinese medicine preparation of cardiovascular disease according to claim 2 is characterized in that the optimum weight percentage ratio of its main constituent is:
Rhizoma Chuanxiong 76.9%, Borneolum Syntheticum 23.1%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510032114 CN1739588A (en) | 2005-09-06 | 2005-09-06 | Chinese medicine prepn for treating cardiac vascular diseases and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510032114 CN1739588A (en) | 2005-09-06 | 2005-09-06 | Chinese medicine prepn for treating cardiac vascular diseases and its prepn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1739588A true CN1739588A (en) | 2006-03-01 |
Family
ID=36092213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510032114 Pending CN1739588A (en) | 2005-09-06 | 2005-09-06 | Chinese medicine prepn for treating cardiac vascular diseases and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1739588A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018040989A1 (en) * | 2016-08-29 | 2018-03-08 | 烟台益诺依生物医药科技有限公司 | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol |
| CN109602710A (en) * | 2019-01-20 | 2019-04-12 | 怀化梅片科技有限公司 | A kind of borneol ball (piece) and preparation method thereof |
-
2005
- 2005-09-06 CN CN 200510032114 patent/CN1739588A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018040989A1 (en) * | 2016-08-29 | 2018-03-08 | 烟台益诺依生物医药科技有限公司 | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol |
| AU2017317950B2 (en) * | 2016-08-29 | 2019-09-19 | Neurodawn Pharmaceutical Co., Ltd. | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol |
| RU2720204C1 (en) * | 2016-08-29 | 2020-04-27 | Яньтай Енэфарма Ко., Лтд. | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol |
| US11135199B2 (en) | 2016-08-29 | 2021-10-05 | Neurodawn Pharmaceutical Co., Ltd. | Sublingual pharmaceutical compositions of edaravone and (+)-2-borneol |
| CN109602710A (en) * | 2019-01-20 | 2019-04-12 | 怀化梅片科技有限公司 | A kind of borneol ball (piece) and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539955A (en) | Drug composition, method for producing the same, and use | |
| CN1824178A (en) | Chinese medicinal preparation for treating urinary system disease, its preparation method and quality control method | |
| CN1739588A (en) | Chinese medicine prepn for treating cardiac vascular diseases and its prepn | |
| CN1857421A (en) | Preparing method of total corydaline extract and corydalis preparation | |
| CN1709363A (en) | Chinese medicine formulation for tonifying spleen to nourish qi, and its preparing method | |
| CN1723945A (en) | Novel oral liquor for invigorating spleen, and prepn. method and quality control therefor | |
| CN1814157A (en) | Chinese medicine preparation for detoxicating and pain-relieving, preparation method and quality control method | |
| CN1739601A (en) | Anticancer Chinese medicine prepn and its prepn process | |
| CN1709369A (en) | Chinese medicine formualtion for waring middle energizer to invigorate spleen, and its preparing method | |
| CN1733204A (en) | Chinese traditional medicine preparation for resolving phlegm and relieving cough and process for preparing the same | |
| CN102028665A (en) | Nimodipine oral fast dissolving tablets and preparation method thereof | |
| CN1724027A (en) | Traditional Chinese medicinal prepn. for treating intestinal tract diseases, and its prepn. method | |
| CN1739579A (en) | Chinese medicine prepn for removing blood stasis and activating blood circulation to dissipate blood stasis and its prepn process | |
| CN100496465C (en) | Chinese medicinal preparation for treating gynecopathy and production thereof | |
| CN1709367A (en) | Chinese medicine formulation for treating dysentery and enteritis, and its preparing method | |
| CN1823897A (en) | Chinese medicinal preparation for antimicrobial and anti inflammation, its preparation method and quality control method | |
| CN1267094C (en) | Orally disintegrating tablet of safflor yellow and its preparation process | |
| CN1739715A (en) | Chinese medicine prepn for nourishing kidney and liver and its prepn process | |
| CN1813882A (en) | Chinese medicine formulation for treating biliary tract disease and its preparing method | |
| CN1739600A (en) | Chinese medicine prepn for treating respiratory tract diseases and its prepn process and quality control method | |
| CN1733068A (en) | Chinese medicinal preparation for promoting blood circulation, dissipating blood stasis, inducing reuscitation with aromatics and preparation process thereof | |
| CN1733253A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1709370A (en) | Chinese medicine formulation for treating digestive tract disease, and its preparation method and quality control method | |
| CN1586494A (en) | Helicidum oral disintegation tablet and its preparing method | |
| CN1626210A (en) | Preparation of 'Sanjin' medication for treating diseases of urinary system and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |